PROCEPT BioRobotics (NASDAQ:PRCT) Given New $50.00 Price Target at TD Cowen

PROCEPT BioRobotics (NASDAQ:PRCT) had its price target trimmed by TD Cowen from $85.00 to $50.00 in a research report released on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts have also weighed in on PRCT. Stephens began coverage on shares of PROCEPT BioRobotics in a report on Wednesday, July 9th. They set an “overweight” rating and a $70.00 price objective for the company. Wall Street Zen raised PROCEPT BioRobotics from a “sell” rating to a “hold” rating in a research note on Saturday, August 9th. Weiss Ratings reissued a “sell (e+)” rating on shares of PROCEPT BioRobotics in a research note on Wednesday, October 8th. Wells Fargo & Company dropped their price objective on PROCEPT BioRobotics from $58.00 to $51.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, Oppenheimer upgraded PROCEPT BioRobotics from a “market perform” rating to an “outperform” rating and set a $60.00 price objective for the company in a report on Tuesday, September 2nd. Nine analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, PROCEPT BioRobotics presently has a consensus rating of “Moderate Buy” and a consensus price target of $63.30.

PROCEPT BioRobotics Stock Performance

Shares of PROCEPT BioRobotics stock opened at $31.61 on Wednesday. The stock’s fifty day moving average is $36.37 and its two-hundred day moving average is $47.93. The company has a market capitalization of $1.76 billion, a PE ratio of -20.66 and a beta of 0.98. The company has a quick ratio of 7.86, a current ratio of 9.21 and a debt-to-equity ratio of 0.13. PROCEPT BioRobotics has a 52 week low of $31.14 and a 52 week high of $103.81.

PROCEPT BioRobotics (NASDAQ:PRCT) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.38) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.03. PROCEPT BioRobotics had a negative net margin of 28.20% and a negative return on equity of 21.56%. The company had revenue of $83.33 million during the quarter, compared to analyst estimates of $80.78 million. During the same quarter last year, the business posted ($0.40) EPS. The firm’s revenue for the quarter was up 42.6% on a year-over-year basis. PROCEPT BioRobotics has set its FY 2026 guidance at EPS. FY 2025 guidance at EPS. As a group, analysts expect that PROCEPT BioRobotics will post -1.75 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the stock. Advisory Services Network LLC raised its position in shares of PROCEPT BioRobotics by 1.3% in the 2nd quarter. Advisory Services Network LLC now owns 20,109 shares of the company’s stock worth $1,158,000 after acquiring an additional 250 shares in the last quarter. Vega Investment Solutions boosted its holdings in shares of PROCEPT BioRobotics by 52.0% in the 2nd quarter. Vega Investment Solutions now owns 775 shares of the company’s stock valued at $45,000 after buying an additional 265 shares in the last quarter. Nisa Investment Advisors LLC boosted its holdings in shares of PROCEPT BioRobotics by 32.5% in the 1st quarter. Nisa Investment Advisors LLC now owns 1,100 shares of the company’s stock valued at $64,000 after buying an additional 270 shares in the last quarter. Frank Rimerman Advisors LLC boosted its holdings in shares of PROCEPT BioRobotics by 0.3% in the 3rd quarter. Frank Rimerman Advisors LLC now owns 122,389 shares of the company’s stock valued at $4,368,000 after buying an additional 307 shares in the last quarter. Finally, RiverPark Advisors LLC boosted its holdings in shares of PROCEPT BioRobotics by 22.5% in the 2nd quarter. RiverPark Advisors LLC now owns 1,761 shares of the company’s stock valued at $101,000 after buying an additional 324 shares in the last quarter. 89.46% of the stock is owned by institutional investors.

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH).